An Open-Label, Single-Treatment, Single-Period, Single Dose, Clinical Phase 1 Study To Assess The Safety And Tolerability Of Recombinant Hepatitis E Vaccine (Adsorbed) Of M/S Cadila Healthcare Ltd., India In Healthy, Adult, Male, Human Subjects.
Latest Information Update: 09 Nov 2020
At a glance
- Drugs Recombinant Hepatitis E Vaccine Cadila Healthcare (Primary)
- Indications Hepatitis E
- Focus Adverse reactions
- Sponsors Cadila Healthcare
Most Recent Events
- 04 Nov 2020 Status changed from recruiting to completed.
- 18 Jun 2020 New trial record